valu usd unless otherwis note
revenu guidanc lower cynosur
view investor expect low go result
howev anticip share weak morn
manag lower revenu guidanc owe mainli continu
cynosur soft reduc price target
revenu beat aid blood screen in-lin ep
report revenu guidanc vs
fce y/i exclud cynosur blood screen
rbce blood screen divest busi drove
revenu beat quarter rel think non-gaap
ep line consensu guidanc higher
revenu lower share count off-set lower non-gaap oper
margin fce non-gaap gm
consensu due geograph product mix
oper expens ratio fce
revenu beat driven blood screen ou breast health
 skelet health breast health revenu fce
y/i rbce y/i highlight intern
breast growth y/i rbce ww intervent
breast solut growth y/i rbce diagnost revenu
fce y/i exclud blood screen
rbce y/i molecular y/i rbce cytology/
perinat revenu y/i rbce flat y/i separ
myosur revenu increas y/i rbce novasur
revenu y/i rbce final cynosur revenu
consensu fce
lower revenu guidanc maintain ep
guidanc manag lower revenu guidanc
vs fce lower guidanc
mainli result reset cynosur expect despit
revenu guidanc reduct manag reiter non-
gaap ep guidanc fce scale back
re-invest tax reform benefit revenu
guidanc came weak fce final
non-gaap ep guidanc fce
cynosur continu disappoint star
show double-digit y/i growth exclud cynosur
blood screen recent acquir ou breast distributor
howev cynosur weak increas novasur competit
continu weigh top-line growth regard cynosur
cynosur build-out complet howev
sale forc hire last year hire last
day product ramp quickli expect manag
reset lofti cynosur expect remain sidelin
pend evid reacceler cynosur gyn surgic
price prior trade day market close estimate unless otherwis note
capit market appreci consider institut investor all-america research survey
believ share perform line
peer group follow key reason
multipl top-lin growth driver lead us
believ return top-lin growth y/i
medium term
molecular diagnost expect continu
take share hpv expand
trichomona market addit full menu viral
load test doubl holx world-wide molecular market
opportun addit recent brought
panther fusion respiratori assay
regard gyn surgic believ mid-single-digit y/i
growth sustain medium term main
growth driver myosur intern expans
addit believ tuck-in acquisit could expand
two product portfolio segment
intern breast health plenti
opportun convert analog user intern market
system could upgrad separ
intern molecular busi grown y/
recent expect magnitud growth
continu also see opportun increas
current liquid-bas cytolog market share
intern market share
attempt transform sustain growth
compani cynosur growth profil still question
cynosur weak increas novasur competit
continu weigh top-lin growth regard
cynosur build-out complet howev
 sale forc hire last
year hire last day product
ramp quickli expect manag reset lofti
cynosur expect remain sidelin
pend evid reacceler cynosur gyn
risk invest thesi
cynosur growth recov bodi contour
market opportun smaller expect
manag spend drive cynosur
bloomberg capit market estim upside/downside/target
base case price target calcul assign
weight intrins valu calcul
ev/ebitda analysi intrins valu
calcul price-to-earnings analysi
intrins valu calcul dcf model
organ top-lin growth medium term
ep growth y/i assum cynosur busi
return mid-single-digit y/i revenu growth period
initi sale disrupt month also assum
molecular diagnost achiev least
high-single-digit y/i growth medium term
upsid scenario valu model
organ top-lin growth next sever
year ep growth rang peer
assum cynosur busi return
y/i revenu growth period initi sale disrupt
month stabil novasur share
loss assum manag drive
sustain superior top-lin growth new contract
win product launch improv intern execut
increas sale forc add tuck-in
downsid scenario valu model organ
top-lin growth low- mid-single-digit rang
ep growth rang assum tomo
placement slow also myosur growth slow
near peak sale novasur continu declin due
increas competit separ assum cynosur
sale disrupt take longer work cynosur
revenu growth slow low mid-single-digit y/i
medium term final gen-prob revenu growth fall short
expect molecular price pressures/reimburs
pressur increas competitor regain share
deriv price target assign weight intrins
valu calcul ev/ebitda analysi weight intrins
valu calcul price-to-earnings analysi weight intrins valu
calcul dcf analysi point averag forward ev/ebitda
multipl large-cap md compani lifesci tool diagnost averag
ev/ebitda averag forward price-to-earnings multipl large-cap md compani
lifesci tool diagnost averag price-to-earnings assign target non-
gaap ebitda multipl large-cap md peer group
multipl equat intrins valu separ assign target forward
price-to-earnings multipl large-cap md peer group multipl
equat intrins valu believ ev/ebitda price-to-earnings multipl
peer warrant given less visibl abil sustain mid-single-digit y/i top-
line growth rel peer near term final base dcf analysi estim
intrins valu dcf analysi use wacc
termin valu ev/ebitda multipl price target support sector perform
risk rate price target
risk price target rate includ risk meaning delay new product
launch market share loss unforeseen chang regulatori environ
lead develop manufactur supplier diagnost product medic
imag surgic product market corpor headquart locat bedford
skelet health medic aesthet
million except per share data
sell market
gener administr
